Hormone care.

Yes, for appropriately evaluated women. Testosterone plays a role in women's health as well as men's. Its strongest clinical evidence is for improving sexual desire and function in appropriately selected women, particularly after menopause. Research on other outcomes is more limited, and benefits demonstrated in men cannot automatically be assumed in women. Evaluation considers your symptoms, health history, goals, and monitoring needs. Women are prescribed a small fraction of a typical male dose, with labs to keep levels in the normal female range. No testosterone product is FDA-approved for women in the US, so treatment is off-label.

Bioidentical means a hormone has the same chemical structure as the one your body makes. FDA-approved estradiol and micronized progesterone are bioidentical and available at retail pharmacies. The word does not mean a product is compounded, natural, safer, or better; those depend on the specific product, dose, and route.

Estradiol and progesterone can be prescribed through your retail pharmacy when appropriate. Medication costs are separate, and insurance may help cover eligible prescriptions. Compounded preparations, when prescribed, are available at an additional cost.

Yes. Hormone management requires an additional membership if you're enrolled in a metabolic program. Peptide management is included with all active memberships, with peptide therapy costs separate.

Yes. You can book a symptom and quality-of-life evaluation, with decisions made case by case alongside your oncology team. Systemic menopausal hormone therapy is generally not recommended after breast cancer. Nonhormonal options are considered first for vaginal and urinary symptoms; selected patients may consider low-dose vaginal estrogen after a shared risk-benefit discussion. This is different from systemic hormone therapy. Anyone taking an aromatase inhibitor needs shared decision-making with their oncologist.